

[About](#)[Products](#)[Pipeline](#)[Research and Development](#)[Regenerative medicine](#)[Pre-clinical and clinical trials](#)[Manufacturing & QA](#)[Partners](#)[Work for us](#)[Contact us](#)[News](#)

Elizaria®

[All products](#)

INN: Eculizumab

A humanized monoclonal antibody that binds to the human complement protein C5 and inhibits the activation of complement-mediated cytotoxicity.



Elizaria® inhibits the activation of the terminal complement component C5, thereby regulating complement activity in the blood.

Elizaria® prevents intravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria (PNH), as well as excessive activation of the complement system in patients with atypical hemolytic uremic syndrome (aHUS).

Eculizumab treatment in patients leads to a significant decrease in the risk of thrombosis, dependence on blood transfusion in patients with hemoglobinuria, and also significantly improves renal function in patients with atypical hemolytic uremic syndrome.

Indications for use:

- Paroxysmal nocturnal hemoglobinuria (PNH)
- Atypical hemolytic uremic syndrome (aHUS)

GENERIUM is the only company in the world that has developed biosimilar of Eculizumab.

Main office

10, ent. 2, Testovskaya st., Moscow,
123112, Russia
Tel: +7 495 988-47-94
Generium@Generium.ru

About

Careers

Our products

Coagil-VII®
Octofactor®
Innonafactor®
Diaskintest®
Infibeta®
T-SPOT®.TB
Tigerase®
Elizaria®
Glurazyme®
Revelise®

All rights reserved. Generium 2019



Site development — **AGIMA**

Tech support — **Techart.**